13D Filing: Armistice Capital and Cerecor Inc (CERC)

Cerecor Inc (NASDAQ:CERC): Steven Boyd’s Armistice Capital filed an amended 13D.

You can check out Armistice Capital’s latest holdings and filings here.

Please follow Armistice Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Armistice Capital or update its stock holdings.

Follow Steven Boyd's Armistice Capital

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Armistice Capital 0 30,155,584 0 30,155,584 30,155,584 74.8%
Armistice Capital Master Fund, Ltd 0 30,155,584 0 30,155,584 30,155,584 74.8%
Steven Boyd 0 30,155,584 0 30,155,584 30,155,584 74.8%

Follow Steven Boyd's Armistice Capital

Page 1 of 11 – SEC Filing

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

WASHINGTON,
DC 20549

SCHEDULE
13D

THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No.3)*

Cerecor Inc.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
15671L109
(CUSIP Number)

Tohuan Steve Chen

c/o Armistice Capital LLC

510 Madison Avenue

22nd Floor

New York, NY 10022

Telephone Number: 212-231-4930

(Name, Address and Telephone Number of Person
Authorized to Receive

Notices and Communications)

August 25, 2017
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [_].
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 2 of 11 – SEC Filing

CUSIP No. 15671L109
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Armistice Capital, LLC
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
(b) [_]
3. SEC USE ONLY
4. SOURCE OF FUNDS
AF
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
[_]
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
7. SOLE VOTING POWER
0
8. SHARED VOTING POWER
30,155,584
9. SOLE DISPOSITIVE POWER
0
10. SHARED DISPOSITIVE POWER
30,155,584
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
30,155,584
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
[_]
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
74.8%
14. TYPE OF REPORTING PERSON
IA, OO

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 3 of 11 – SEC Filing

CUSIP No. 15671L109
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Armistice Capital Master Fund, Ltd.
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
(b) [_]
3. SEC USE ONLY
4. SOURCE OF FUNDS
WC
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
[_]
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
7. SOLE VOTING POWER
0
8. SHARED VOTING POWER
30,155,584
9. SOLE DISPOSITIVE POWER
0
10. SHARED DISPOSITIVE POWER
30,155,584
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
30,155,584
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
[_]
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
74.8%
14. TYPE OF REPORTING PERSON
CO

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 4 of 11 – SEC Filing

CUSIP No. 15671L109
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Steven Boyd
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
(b) [_]
3. SEC USE ONLY
4. SOURCE OF FUNDS
AF
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
[_]
6. CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
7. SOLE VOTING POWER
0
8. SHARED VOTING POWER
30,155,584
9. SOLE DISPOSITIVE POWER
0
10. SHARED DISPOSITIVE POWER
30,155,584
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
30,155,584
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
[_]
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
74.8%
14. TYPE OF REPORTING PERSON
IN, HC

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 5 of 11 – SEC Filing

CUSIP No. 15671L109
Item 1. Security and Issuer.
The name of the issuer is Cerecor Inc., a Delaware corporation (the “Issuer”).  The address of the Issuer’s principal executive offices is 400 E. Pratt Street, Suite 606, Baltimore, Maryland 21202.  This Amendment No. 3 to Schedule 13D relates to the Issuer’s Common Stock, $0.001 par value (the “Shares”).
Item 2. Identity and Background.
(a), (f) The persons filing this statement are Armistice Capital, LLC, a Delaware limited liability company (“Armistice Capital”), Armistice Capital Master Fund, Ltd., a Cayman Islands corporation (the “Master Fund”), and Steven Boyd, a United States citizen (“Mr. Boyd”, and collectively with Armistice Capital and the Master Fund, the “Reporting Persons”).
(b), (c)

Armistice Capital is an investment adviser
registered with the Securities and Exchange Commission (the “SEC”) that is principally engaged in the business of providing
investment management services to private investment vehicles, including the Master Fund. The principal business address of Armistice
Capital is 510 Madison Avenue, 22nd Floor, New York, New York 10022.

The Master Fund is principally engaged in the
business of investing in securities. The principal business address of the Master Fund is c/o dms Corporate Services Ltd., 20 Genesis
Close, P.O. Box 314, Grand Cayman KY1-1104, Cayman Islands. The board of directors of the Master Fund consists of Steven Boyd,
Kevin A. Phillip and Gregory S. Bennett.

Steven Boyd is the managing member of Armistice
Capital and a director of the Master Fund. Mr. Boyd’s business address is 510 Madison Avenue, 22nd Floor, New
York, New York 10022.

(d) None of the Reporting Persons have, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) None of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 6 of 11 – SEC Filing

Item 3. Source and Amount of Funds or Other Consideration.
The funds for the purchase of the 30,155,584 Shares beneficially owned by the Reporting Persons came from working capital of the Master Fund, which is the direct owner of the Shares.  The net investment costs (including commissions, if any) of the Shares beneficially owned by the Reporting Persons is approximately $5,900,070.  No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes (including certain leverage arrangements) in the ordinary course of business.
Item 4. Purpose of Transaction.

The Reporting Persons are filing this Schedule
13D/A to report a change in their beneficial ownership percentage of the Shares, as indicated in Item 5 below.

On April 27, 2017, the Issuer and the Master
Fund entered into a securities purchase agreement (the “Securities Purchase Agreement”), pursuant to which the Master
Fund agreed to purchase $5 million of the Issuer’s securities, consisting of (i) 2,345,714 Shares at a purchase price of
$0.35 per share, subject to adjustment as provided in the Securities Purchase Agreement, (ii) 4,179 shares of the Issuer’s
newly-created Series A Convertible Preferred Stock, which are convertible into 11,940,000 Shares at a conversion price of $0.35
per share, subject to adjustment as provided in the Securities Purchase Agreement, and (iii) warrants to purchase up to 14,285,714
Shares at an exercise price of $0.40 per share, subject to adjustment as provided in the Securities Purchase Agreement (collectively,
the “Warrants”). Each share of the Series A Convertible Preferred Stock is convertible at any time at the option of
the Master Fund and has no expiration date. The Warrants are exercisable at any time at the option of the Master Fund and expire
on June 30, 2022. The Securities Purchase Agreement also provides the Master Fund with certain participation rights in respect
of future financings conducted by the Issuer. Pursuant to NASDAQ Capital Market rules and regulations, the Series A Preferred Stock
became convertible into Shares, and the Warrants became exercisable, upon the shareholders of the Issuer approving the private
placement on June 30, 2017. The Reporting Persons have since converted all of their shares of Series A Preferred Stock into Shares.

In addition, pursuant to the terms of the Issuer’s
Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “Certificate”),
(i) as long as the Master Fund maintains beneficial ownership of at least 13% of the Shares, the Master Fund exclusively and as
a separate class, will be entitled to elect two directors to the Issuer’s board of directors (the “Board of Directors”),
and (ii) as long as the Master Fund maintains beneficial ownership of at least 10% of the Shares, the Master Fund exclusively and
as a separate class, will be entitled to elect one director to the Board of Directors. In this regard, on May 15, 2017, the Issuer
issued a press release to announce that Mr. Boyd and Peter Greenleaf, an individual recommended by Mr. Boyd that is not affiliated
with the Reporting Persons, were appointed to the Board of Directors.

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 7 of 11 – SEC Filing

In connection with the private placement, the
Issuer and the Master Fund also entered into a Registration Rights Agreement on April 27, 2017 (the “Registration Rights
Agreement”), pursuant to which the Issuer has agreed to file one or more registration statements registering for resale the
Shares sold in the private placement and the Shares issuable upon exercise of the Warrants and conversion of the Series A Preferred
Stock.

On April 28, 2017, the Issuer issued a press
release (the “Press Release”) to announce the closing of the $5 million private placement. Among other things, the
Press Release summarizes the material terms of the Securities Purchase Agreement, sets forth how the proceeds of the transaction
are anticipated to be used, and announces the rescheduling of the Issuer’s annual meeting of shareholders to June 30, 2017.

The foregoing was a summary of the Press
Release and certain material terms of the Securities Purchase Agreement, the Certificate, and the Registration Rights Agreement.
The foregoing descriptions are not, and do not purport to be, complete and are qualified in their entirety by reference to the
full text of those documents, which have been filed as Exhibits C, D, E and F, respectively, and are incorporated herein by reference.

The Reporting Persons intend to review
their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer’s
financial position, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions,
the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate
including, without limitation, participating on the Board of Directors, engaging in discussions with stockholders of the Issuer
and others about the Issuer and the Reporting Persons’ investment, proposing changes to the Issuer’s development plans for
CERC-501, CERC-301 and CERC-611, reshaping the Issuer’s corporate strategy, recommending business development transactions,
proposing changes to management, operations and the structure of the Board of Directors (including the composition of the Board
of Directors), purchasing additional Shares, selling some or all of their Shares, engaging in short selling of or any hedging or
similar transaction with respect to the Shares, or changing their intention with respect to any and all matters referred to in
subparagraphs (a) – (j) of Item 4 of Schedule 13D.

Except as otherwise set forth herein, the Reporting
Persons do not have any present plans or proposals which would relate to, or result in, the matters set forth in subparagraphs
(a) – (j) of Item 4 of Schedule 13D. However, subject to market conditions and in compliance with applicable securities laws,
the Reporting Persons reserve the right, at a later date, to affect one or more of such changes. The Reporting Persons may change
the number of Shares they may be deemed to beneficially own in open-market transactions or privately negotiated transactions. The
Reporting Persons may also communicate with the Issuer’s management, Board of Directors and other holders of Shares from
time to time.

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 8 of 11 – SEC Filing

Item 5. Interest in Securities of the Issuer.
(a) – (d)

As of the date hereof, each of the Reporting
Persons may be deemed to be the beneficial owner of 30,155,584 Shares, constituting 74.8% of the Shares, based upon 40,340,571
Shares outstanding as of the date hereof as adjusted for the Warrants beneficially owned by the Reporting Persons. Each of the
Reporting Persons has the sole power to vote or direct the vote of 0 Shares and the shared power to vote or direct the vote of
30,155,584 Shares. Each of the Reporting Persons has the sole power to dispose or direct the disposition of 0 Shares and the shared
power to dispose or direct the disposition of 30,155,584 Shares. Other than the Shares beneficially owned by the Reporting Persons
pursuant to the Securities Purchase Agreement (as summarized in Item 4 above), the Shares beneficially owned by the Reporting Persons
were purchased in open market transactions.

The transactions in the Shares by the Reporting
Persons since the last Schedule 13D/A filed by the Reporting Persons are set forth on Exhibit B.

(e)

N/A

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

The information set forth in Item 4 above is
incorporated by reference in its entirety in this Item 6. The Reporting Persons do not have any contract, arrangement, understanding
or relationship with any person with respect to securities of the Issuer that is not described in Item 4 above and/or incorporated
herein by reference.

Item 7. Material to be Filed as Exhibits.
Exhibit A: Joint Filing Agreement
Exhibit B: Schedule of Transactions in the Shares
Exhibit C: Press Release of Cerecor Inc., dated April 28, 2017 (incorporated by reference to Exhibit 99.1 to the Form 8-K filed with the SEC by the Issuer on April 28, 2017)
Exhibit D: Securities Purchase Agreement, dated April 27, 2017 (incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC by the Issuer on April 28, 2017)
Exhibit E: Form of Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock of Cerecor Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed with the SEC by the Issuer on April 28, 2017)
Exhibit F: Registration Rights Agreement, dated April 27, 2017 (incorporated by reference to Exhibit 10.2 to the Form 8-K filed with the SEC by the Issuer on April 28, 2017)

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 9 of 11 – SEC Filing

SIGNATURE

After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

August 30, 2017
(Date)
Armistice Capital, LLC*
By:  /s/ Steven Boyd

Name: Steven Boyd

Title: Managing Member

Armistice Capital Master Fund, Ltd.
By:  /s/ Steven Boyd

Name: Steven Boyd

Title: Director

Steven Boyd*
/s/ Steven Boyd

* The Reporting Person disclaims beneficial
ownership of the reported securities except to the extent of its pecuniary interests therein, and this report shall not be deemed
an admission that such person is the beneficial owner of these securities for purposes of Section 16 of the U.S. Securities Exchange
Act of 1934, as amended, or for any other purpose.

Attention: Intentional misstatements or omissions of fact constitute
Federal criminal violations (see 18 U.S.C. 1001).

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 10 of 11 – SEC Filing

Exhibit A

AGREEMENT

The undersigned agree that
this Amendment No. 3 to Schedule 13D, dated August 30, 2017, relating to the Common Stock, $0.001 par value, of Cerecor Inc. shall
be filed on behalf of the undersigned.

August 30, 2017
(Date)
Armistice Capital, LLC
By:  /s/ Steven Boyd

Name: Steven Boyd

Title: Managing Member

Armistice Capital Master Fund, Ltd.
By:  /s/ Steven Boyd

Name: Steven Boyd

Title: Director

Steven Boyd
/s/ Steven Boyd

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 11 of 11 – SEC Filing

Exhibit B

Schedule of Transactions in the
Shares

Trade Date Purchase/Sale Quantity Price
7/06/2017 Purchase* 11,940,000 $0.35*
8/14/2017 Purchase 175,776 $0.64
8/15/2017 Purchase 65,500 $0.58
8/16/2017 Purchase 76,800 $0.58
8/17/2017 Purchase 26,002 $0.5863
8/18/2017 Purchase 31,698 $0.6091
8/21/2017 Purchase 15,564 $0.6126
8/22/2017 Purchase 19,301 $0.6163
8/23/2017 Purchase 900 $0.6186
8/24/2017 Purchase 19,944 $0.6991
8/25/2017 Purchase 38,328 $0.7538
8/28/2017 Purchase 25,321 $0.7257
8/29/2017 Purchase 50,000 $0.7159
8/30/2017 Purchase 512 $0.736

* The Reporting Persons converted their 4,179
shares of the Issuer’s Series A Convertible Preferred Stock into 11,940,000 Shares at the conversion price of $0.35 per share.

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)